BDNF Polymorphism: A Review of Its Diagnostic and Clinical Relevance in Neurodegenerative Disorders
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Brain-derived neurotrophic factor (BDNF) has a unique role in the neuronal development, differentiation, and survival in the developing and adult nervous system. A common single-nucleotide polymorphism in the pro-region of the human BDNF gene, resulting in a valine to methionine substitution (Val66Met), has been associated with the susceptibility, incidence, and clinical features of several neurodegenerative disorders. Much research has been dedicated to evaluating the effects of polymorphism in the past decade, and functional effects of this genetic variation. A better understanding of how this naturally occurring polymorphism associates with or influences physiology, anatomy, and cognition in both healthy and diseased adults in neurodegenerative conditions will help understand neurochemical mechanisms and definable clinical outcomes in humans. Here we review the role and relevance of the BDNF Val66Met polymorphism in neurodegenerative diseases, with particular emphasis on glaucoma, multiple sclerosis (MS), Alzheimer's disease (AD) and Parkinson's disease (PD). Several controversies and unresolved issues, including small effect sizes, possible ethnicity, gender, and age effects of the BDNF Val66Met are also discussed with respect to future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“For instance, genes encoding amyloid precursor protein [96], presenilin 1 [97], and presenilin 2 [98] confer”
BackgroundDomingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 8×
“The C270T (rs56164415) polymorphism located in the non-coding region of BDNF was found to be associated with increased risk of late-onset Alzheimer’s disease (LOAD) and also linked with susceptibility to and the onset of MS [37, 38].”
BackgroundInfluentialPathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Neurotrophin-regulated signalling pathways
Reichardt, L. F. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1894 · Cited by 2,195
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 1×
“For instance, genes encoding amyloid precursor protein [96], presenilin 1 [97], and presenilin 2 [98] confer”
BackgroundRisk Alleles for Multiple Sclerosis Identified by a Genomewide Study
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa073493 · Cited by 1,746
Hippocampal volume and depression: a meta-analysis of MRI studies
Videbech, P., & Ravnkilde, B. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.1957 · Cited by 1,590 · cited 1×
“An 11% volumetric decrease of the hippocampal region (a significant reduction that is comparable to that associated with diseased conditions such as major depression [132]) has been associated with the BDNF Met allele carriage in healthy subjects [133].”
BackgroundHippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor.
Korte, M., Carroll, P., Wolf, E., Brem, G., Thoenen, H., & Bonhoeffer, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8856 · Cited by 1,426 · cited 1×
“While the application of exogenous BDNF was shown to facilitate LTP, the decrease of BDNF levels by gene knock-out in mice attenuated LTP in the hippocampus [14, 15].”
BackgroundNeurotrophin-3: a Neurotrophic Factor Related to NGF and BDNF
Maisonpierre, P. C., Belluscio, L., Squinto, S., Ip, N. Y., Furth, M. E., Lindsay, R. M., & Yancopoulos, G. D. (1990) · Science · doi:10.1126/science.2321006 · Cited by 1,322
Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00181-1 · Cited by 1,151 · cited 1×
“It has also been demonstrated that BDNF concentration is reduced in individuals with major depression and increases after antidepressant drug treatment [12].”
BackgroundFigurov, A., Pozzo-Miller, L. D., Olafsson, P., Wang, T., & Lu, B. (1996) · Nature · doi:10.1038/381706a0 · Cited by 1,106 · cited 1×
“While the application of exogenous BDNF was shown to facilitate LTP, the decrease of BDNF levels by gene knock-out in mice attenuated LTP in the hippocampus [14, 15].”
BackgroundPezawas, L., Verchinski, B. A., Mattay, V. S., Callicott, J. H., Kolachana, B. S., Straub, R. E., Egan, M. F., Meyer-Lindenberg, A., & Weinberger, D. R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2680-04.2004 · Cited by 890
GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820
Mansour-Robaey, S., Clarke, D. B., Wang, Y. C., Bray, G. M., & Aguayo, A. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.5.1632 · Cited by 731
Pruunsild, P., Kazantseva, A., Aid, T., Palm, K., & Timmusk, T. (2007) · Genomics · doi:10.1016/j.ygeno.2007.05.004 · Cited by 699 · cited 1×
“The BDNF gene is localized on chromosome 11 band p13 [4] and comprises 11 exons and 9 functional promoters [21].”
BackgroundThe Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) (2009) · Nature Genetics · doi:10.1038/ng.396 · Cited by 550
Hock, C., Heese, K., Hulette, C., Rosenberg, C., & Otten, U. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.846 · Cited by 523 · cited 1×
“BDNF is widely expressed in the CNS, and its expression is decreased in several neurodegenerative diseases as demonstrated by post-mortem studies, including in AD [7-9], PD [10], and Huntington’s disease (HD) [11].”
BackgroundReduced BDNF mRNA Expression in the Parkinson's Disease Substantia Nigra
Howells, D. W., Porritt, M. J., Wong, J. Y. F., Batchelor, P. E., Kalnins, R., Hughes, A. J., & Donnan, G. A. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7483 · Cited by 513
Scalzo, P., Kümmer, A., Bretas, T. L., Cardoso, F., & Teixeira, A. L. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5357-2 · Cited by 299 · cited 1×
“The serum BDNF levels were also found to be decreased in PD subjects [112].”
BackgroundNotaras, M., Hill, R., & van den Buuse, M. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.27 · Cited by 274
Population genetic study of the brain-derived neurotrophic factor (BDNF) gene
Petryshen, T. L., Sabeti, P. C., Aldinger, K. A., Fry, B., Fan, J. B., Schaffner, S. F., Waggoner, S. G., Tahl, A. R., & Sklar, P. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.24 · Cited by 267 · cited 3×
“The higher Met allele frequency and occurrence of Met homozygotes in Asian population may provide an opportunity for such studies [24, 32].”
BackgroundBDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease
Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Pietrzak, R. H., Ellis, K. A., Harrington, K. D., Bourgeat, P., Salvado, O., Darby, D., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.006 · Cited by 124
Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Pietrzak, R. H., Ellis, K. A., Harrington, K., Bourgeat, P., Bush, A. I., Martins, R. N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086498 · Cited by 110 · cited 2×
“In addition, it has been suggested that the BDNF Val66Met polymorphism moderates the memory decline and hippocampal atrophy in prodromal AD subjects with high baseline levels of Aβ [100].”
BackgroundLim, Y. Y., Hassenstab, J., Cruchaga, C., Goate, A., Fagan, A. M., Benzinger, T. L. S., Maruff, P., Snyder, P. J., Masters, C. L., Allegri, R., et al. (2016) · Brain · doi:10.1093/brain/aww200 · Cited by 76
Val66Met BDNF polymorphism is associated with Parkinson's disease cognitive impairment
Altmann, V., Schumacher-Schuh, A. F., Rieck, M., Callegari-Jacques, S. M., Rieder, C. R. M., & Hutz, M. H. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.01.030 · Cited by 43
Cited by
Almeida, F. B., Barros, H. M. T., & Pinna, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041758 · Cited by 57
The relevance of BDNF for neuroprotection and neuroplasticity in multiple sclerosis
Maiworm, M. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1385042 · Cited by 27
Metadata
- Authors
- Shen, T., You, Y., Joseph, C., Mirzaei, M., Klistorner, A., Graham, S. L., & Gupta, V.
- Venue
- Aging and disease
- Publisher
- Aging and Disease
- Published
- 2018
- Volume
- 9
- Issue
- 3
- Pages
- 523
- ISSN
- 2152-5250 (ISSN-L)
- OpenAlex
- W2795176598
- Cited by
- 144
- References
- 28
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.